01 What is Cerebrolysin?
In plain English.
Cerebrolysin is not a single peptide, it is a mixture of low-molecular-weight peptides and free amino acids produced by the standardised enzymatic breakdown of purified pig brain protein. It has been on the market since the 1970s, is manufactured by Ever Neuro Pharma in Austria, and is given by injection ([intramuscular](/glossary "Intramuscular: Injected into muscle tissue; typically a deeper, larger volume than a subcutaneous injection.")) or intravenous infusion. It is approved in roughly 50 countries, Austria, several Central and Eastern European states, Russia, China, India, parts of Asia and Latin America, for conditions where doctors want to nudge the brain to recover after damage: acute ischaemic stroke, vascular dementia, traumatic brain injury and Alzheimer's disease. It is not FDA-approved in the United States and has no central EMA marketing authorisation. The biggest tension in the Cerebrolysin story is that very large Cochrane reviews of its use in acute stroke have come down against it, even while it remains in routine clinical use across much of the world.
Two things make Cerebrolysin unusual. First, it is a mixture, not a defined molecular entity, every ampoule contains a characterised distribution of peptide fragments and amino acids rather than a single drug substance. Second, the regulatory and evidence pictures point in different directions. It carries on-label approvals in roughly 50 countries and is widely used in stroke and dementia practice across Eastern Europe, Russia, China and Asia, yet successive Cochrane reviews of its use in acute ischaemic stroke (Ziganshina and colleagues, 2010 → 2023) have found no benefit on death or disability and a possible increase in serious adverse events. That gap is the most important fact about the molecule.
02 How it works
The simple version, then the science.
Cerebrolysin is described by its manufacturer as having neurotrophic-like activity, that is, it is claimed to mimic the small protein signals ("neurotrophic factors") that brain cells use to survive, grow and repair connections. In animal models of stroke and brain injury, Cerebrolysin appears to reduce neuronal death, encourage new synaptic connections and dampen inflammatory damage in the days after injury. The clinical hope is that giving it shortly after a stroke or in the early stages of dementia helps the brain recover or slows decline. Whether those animal-model effects translate into measurable patient benefit is exactly what the human trials have been arguing about for the last twenty years.
Go deeper · the proposed mechanism
Cerebrolysin is produced by standardised enzymatic hydrolysis of purified porcine brain protein. The resulting preparation is approximately 25% low-molecular-weight peptides (≤10 kDa) and 75% free [amino acids](/glossary "Amino acid: The building blocks of proteins. A peptide is a short chain of them linked together."). Preclinical work (largely industry-supported) reports neurotrophic-factor-like activity overlapping with CNTF, GDNF, BDNF and NGF signalling, alongside anti-apoptotic, anti-excitotoxic and anti-inflammatory effects in rodent stroke and TBI models. A subset of the peptide fragments is reported to cross the blood-brain barrier, although the relevance of that finding for clinical effect in humans is unclear. Because the product is a mixture rather than a defined single molecule, traditional pharmacokinetic parameters (half-life, AUC, Cmax) do not apply in the way they would for a small molecule or a single peptide. This is also part of why Western regulators have been more cautious than their Eastern European, Russian, Chinese and Indian counterparts.
03 What it's used for
Each use graded by how strong the evidence actually is.
- ApprovedAcute ischaemic stroke (in approved countries)Approved in roughly 50 countries for acute ischaemic stroke, typically given as a daily intravenous infusion within the first 24–72 hours and continued for around 10–21 days. The most-cited trial is CARS (Cerebrolysin and Recovery After Stroke; Muresanu et al., Stroke 2016), a 208-patient placebo-controlled RCT that reported an improvement on a multimodal motor-function score. The earlier and larger CASTA trial in Asia (Heiss et al., Stroke 2012, 1,070 patients) was negative on its primary endpoint. The 2023 Cochrane review (Ziganshina et al.) concluded that current evidence does not support a benefit on death or disability and signalled a possible excess of serious adverse events. NOT an FDA/EMA indication.
- ModerateVascular dementia (in approved countries)Approved in several jurisdictions as an adjunct in vascular dementia, typically given in cycles of daily infusion for several weeks. Trial evidence is largely from Eastern European, Russian and Chinese groups; reported benefits on cognitive scales (ADAS-cog, MMSE) and global function are real but the trial network is narrow and the meta-analytic certainty is low.
- ModerateAlzheimer's disease, adjunct (in approved countries)A small set of placebo-controlled RCTs (Ruether et al., Int Clin Psychopharmacol 2001; Panisset et al., J Neural Transm 2002) reported cognitive and global-function improvements in mild-to-moderate Alzheimer's disease over 4–6 months. The signal was real in those individual trials but the patient numbers are modest and the indication has not been pursued through the FDA or EMA. Not part of any Western Alzheimer's treatment guideline.
- ModerateTraumatic brain injury (in approved countries)Approved as an adjunct in moderate-to-severe TBI in several countries. The CAPTAIN programme (Cerebrolysin And Prognosis in Traumatic brain INjury) studied moderate-to-severe TBI; CAPTAIN-II reported improvements on composite recovery scales but the trial network is again limited, and the indication is not FDA/EMA-recognised.
- LimitedPost-stroke aphasia and motor recoveryA growing set of smaller RCTs (e.g. ESCAS, 2025) suggest a possible adjunctive benefit when combined with speech or motor rehabilitation in the weeks after stroke. The studies are small, the heterogeneity is high, and these are not standalone licensed indications anywhere.
- Anecdotal"Nootropic" / general cognitive enhancement / longevityThe dominant non-clinical use case. There are essentially zero trials of Cerebrolysin in healthy adults for cognitive enhancement, recovery from concussion in athletes, or longevity. The wellness positioning rests on extrapolation from the approved disease indications and on testimony, not on direct evidence in healthy people.
04 What the evidence says
The evidence base is large but contested. The CARS trial (Muresanu et al., Stroke 2016; n=208) reported improvement on a multimodal motor-function composite in early ischaemic-stroke patients receiving Cerebrolysin alongside rehabilitation, the most-cited modern positive result. The larger CASTA trial (Heiss et al., Stroke 2012; n=1,070 across Asia) was negative on its primary mRS endpoint. In Alzheimer's disease, Ruether et al. (Int Clin Psychopharmacol 2001) and Panisset et al. (J Neural Transm 2002) reported cognitive and global-function improvements over 4–6 months in modest-sized RCTs. In TBI, the CAPTAIN-II programme has reported composite recovery benefits. The most important counterweight is the Cochrane series: Ziganshina and colleagues have published successive Cochrane reviews on Cerebrolysin in acute stroke (2010, 2015, 2016, 2017, 2020, 2023). The 2023 update concluded that the current body of evidence does not support a benefit on death or disability in acute ischaemic stroke and noted a possible increase in serious adverse events. Honest caveats throughout: most positive trials are sponsor-linked or single-region, blinding has been questioned, the comparator is usually placebo plus standard care, the product is a mixture rather than a defined molecule, and the FDA and EMA have not licensed it.
05 Dosing & administration
Reported in the literature, information not advice.
For information only, Cerebrolysin is a prescription medicine in the countries that approve it and must be administered by a clinician in a clinical setting. Typical published protocols in acute ischaemic stroke use 30 mL daily by intravenous infusion for 10–21 consecutive days, usually starting within 24–72 hours of symptom onset (this is the schedule used in CARS and CASTA). In dementia indications, lower-volume IM injection or shorter infusion cycles (e.g. 10–30 mL on weekdays for 4 weeks, repeated as cycles) are typical. In traumatic brain injury, higher-volume daily infusions over 10–30 days have been studied. None of these protocols is validated by the FDA, EMA or MHRA. The off-label use of Cerebrolysin as a "nootropic" by self-administration via the research-chemical channel is a different category of risk entirely: the product is intended for clinician-administered infusion, not for self-dosing, and any self-administration adds an unverified supply route on top of an unevidenced indication.
06 Side effects & safety
In trial populations Cerebrolysin has generally been reported as well-tolerated, with most adverse events mild and similar to placebo. The commonest are dizziness, headache, mild flushing or sweating during infusion, and occasional injection-site reactions or low-grade fever. Serious adverse events are uncommon individually but the 2023 Cochrane review flagged a possible increase in serious adverse events in stroke trials as a whole, a signal worth taking seriously when weighing the unclear benefit. Because Cerebrolysin is derived from porcine brain tissue, theoretical safety considerations include allergy/hypersensitivity (it is contraindicated in those with severe allergy to the product), epilepsy (some labels caution use in patients with grand mal seizure history), and severe renal impairment. The product is not recommended in pregnancy and breastfeeding because adequate human data are lacking. The porcine origin is also relevant for some patients on religious or dietary grounds, clinician disclosure is normal practice in approved jurisdictions.
07 Where to buy (research use only)
Vetted on quality and transparency, not an endorsement to use.
08 Legal & regulatory status
- UKNot licensed by the MHRA. No UK marketing authorisation, no NHS provision, no regulated retail supply. Use at private clinics would rely on unlicensed-medicine or personal-import routes; pharmacovigilance and standard patient protections do not apply in the same way as for a UK-licensed product.
- USNOT FDA-approved. Cerebrolysin has never received US marketing approval for any indication. It is not legally available through US pharmacies for clinical use. Importation for personal use exists as a narrow exception under FDA enforcement discretion but is not a licensed supply route.
- EUNo central EMA marketing authorisation exists for Cerebrolysin. Several EU member states, including Austria (where the manufacturer is based) and a number of Central/Eastern European countries, license it at national level and it is available there on prescription. In other EU states it is not licensed and would require unlicensed-medicine routes.
- Rest of worldLicensed in approximately 50 countries, including Austria, Germany (under specific conditions), several Central/Eastern European states, Russia, China (a major market), India, parts of South-East Asia and Latin America. In those countries it is a prescription medicine, typically administered in stroke, neurology, geriatric or rehabilitation clinical settings.
- SportCerebrolysin is not currently listed on the WADA Prohibited List. The product is also not used in performance contexts in any evidenced way. Athletes under WADA jurisdiction should still check the current published list and confirm with their anti-doping authority before use.
09 Clinical studies & research
Primary sources. Read the science yourself.